IMR Press / EJGO / Volume 36 / Issue 2 / DOI: 10.12892/ejgo2586.2015

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Experimental Research
Protective and sensitive effects of melatonin combined with adriamycin on ER+ (estrogen receptor) breast cancer
Show Less
1 Department of Oncology, the First Hospital of Shijiazhuang, Shijiazhuang
2 Department of Clinical Laboratory, the First Hospital of Shijiazhuang, Shijiazhuang (P.R. China)
Eur. J. Gynaecol. Oncol. 2015, 36(2), 192–196;
Published: 10 April 2015

Objective: This study aims to investigate the protective and sensitive effects of melatonin (MLT) in the treatment of breast cancer. Materials and Methods: ER+ breast cancer rat model was established and then rats were randomly divided into five different groups as follows: control group, Diss group, adriamycin (ADM) group, MLT group, and MLT combined with adriamycin (M+A) group. Tumor weights and one month survival rate were compared among these groups. In addition, changes of tumor tissues and expression of Ecadherin were observed under optical microscopy or electro-microscopy. Results: Tumor weights were significantly lighter in M+A group than those in ADM group (p < 0.05). Under optical and electro-microscopy, tumor cell apoptosis was obviously increased in MLT group, and tumor cell injury was more severe in M+A group than that in ADM group; additionally, expression of E-cadherin was higher in MLT group and M+A group than that in other groups. Moreover, MLT group had the highest one month survival rate (100%), there was the poorest life quality in ADM group, but the best life quality in MLT. Conclusion: MLT could enhance the sensitivity of tumor to ADM in vivo and improve patient’s life quality.
Breast cancer
Back to top